Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > COLUMN
COLUMN
- AI in HR: Navigating the Ethical Minefield
November 28, 2025
- The Unseen Edge & the Shadow of Bias: Awareness as the Cornerstone of Leadership Success
October 31, 2025
- The Keen Eye: Awareness as a Leadership Cornerstone
September 29, 2025
- A “50-Billion-Yen Plus” Newcomer
September 4, 2025
- AI in Japanese Pharma: Now, Not Later!
August 29, 2025
- Beyond the Bench: Why Biopharma Needs Strategic Thinkers
July 28, 2025
- AI Is Redefining Healthcare: Insights from Prospection Japan’s Conference
June 27, 2025
- Bridging the Talent Gap: Communication Challenges in Japan’s Pharma & Multinationals
May 30, 2025
- The Evolution of HR: From BP to Agile
April 28, 2025
- Build a Strong Employer Brand - What Can You Do If Your Company Stinks?
March 19, 2025
- 4 Things Your Firm Can Do to Attract and Retain Top Talent in Japan’s Pharmaceutical and Medical Device Industry
February 14, 2025
- A Conversation with Bill Schuster: Navigating the Complexities of Healthcare Leadership
January 24, 2025
- A Conversation with James Feliciano: Navigating the Complexities of the Japanese Pharmaceutical Industry
December 23, 2024
- How to Be a Country Manager
November 29, 2024
- Elevating Leadership: Insights from Japan’s Healthcare Sector
October 23, 2024
- 6 Tips for Motivating and Engaging Current Employees
September 30, 2024
- Why LinkedIn Isn’t Effective in Japan
August 27, 2024
- The Dynamics of Field Medical Visits: Importance of Balancing Quality and Frequency in Medical Interactions
August 2, 2024
- 3 Common Mistakes Made when Hiring a Leader
July 25, 2024
- 3 Tips for Establishing Local Connections in Japan
June 28, 2024
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s drug pricing panel on November 19 discussed a wide range of potential pricing changes related to patent-protected medicines, including…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…